跳至主要内容
临床试验/NCT02294188
NCT02294188已完成不适用

Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia

University of Notre Dame1 个研究点 分布在 1 个国家目标入组 1,519 人开始时间: 2015年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
1,519
试验地点
1
主要终点
Malaria Incidence

研究概览

简要总结

The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of spatial repellent products in reducing the incidence of malaria infection in human cohorts. The null hypothesis (H0) is that there is no difference in malaria incidence between intervention and control arms.

详细描述

The primary epidemiological endpoint will be the incidence density of first time malaria infections among human cohorts during the follow-up period as detected by polymerase chain reaction assay (PCR). This measure will inform PE (the reduction of incidence) between intervention and control study arms using the formula: PE =[(Ip - Ia)/Ip]* 100%; based on an expected minimum effect size of 30%. First time infections in these subjects will offer relatively unambiguous evidence of the extent of exposure to infectious mosquito bites. The primary entomological endpoint will be adult densities of vector species via human-landing catch (HLC) from sentinel households from intervention and control arms over the follow-up period.

Secondary epidemiological endpoints will be the incidence density of first time malaria infections among human cohorts during the follow-up period as detected by microscopy and the total number of cases averted (i.e., all Plasmodium spp. infections in cohort subjects). Secondary entomological endpoints include number of sporozoite infected mosquitoes, parity and species-specific effects of the spatial repellent product.

Both epidemiological and entomological endpoints will be utilized to look at the relationship between SR and PE based on product coverage (to include diversion and community effects) and insect behavior. The prospect of SR associated temporal cumulative effects on study endpoints (epidemiological and entomological) over transmission seasons will also be investigated by using the cumulative incidence of infection over the season and applying a survival curve analysis of the cohort data.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Months 至 59 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Children aged 6-59 months
  • glucose-6-phosphate dehydrogenase (G6PD) normal (qualitative screen) in sites where P. vivax or P. ovale known prevalence rates represent major burden) and whose treatment with primaquine is implemented within national guidelines
  • Hb > 5mg/dl
  • Temperature ≤38.0°C) and no moderate or severe acute illness/infection on the day of inclusion
  • Sleeps in cluster >90% of nights during any given month
  • No plans for extended travel (<1month) outside of home during study
  • Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
  • Provision of assent/informed consent form signed by the subject and by the parent(s) or another legally acceptable representative

排除标准

  • children < 6 months or > 5 years
  • G6PD deficiency (qualitative screen) in sites where P. vivax or P. ovale known prevalence rates represent major burden and whose treatment with primaquine is implemented within national guidelines
  • Severe anemia
  • Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of inclusion
  • Sleeps in cluster <90% of nights during any given month
  • Plans for extended travel (>1month) outside of home during study
  • Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
  • No provision of assent/informed consent form signed by the subject and by the parent(s) or another legally acceptable representative

研究组 & 干预措施

Placebo

Placebo Comparator

Spatial Repellent product without active ingredient (SHIELD)

干预措施: Spatial Repellent product without active ingredient (SHIELD) (Device)

Intervention

Active Comparator

Spatial Repellent product with active ingredient (SHIELD)

干预措施: Spatial Repellent product with active ingredient (SHIELD) (Device)

Intervention

Active Comparator

Spatial Repellent product with active ingredient (SHIELD)

干预措施: Active ingredient (Device)

结局指标

主要结局

Malaria Incidence

时间窗: 104 weeks

Incidence of malaria infections among human cohorts during the follow-up period as detected by PCR

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Spatial Repellent Products for Control of Vector... | 临床试验